Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × abagovomab × Gynecologic × Clear all

Phase

Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 9 Carboplatin 8 Cisplatin 7 liposomal doxorubicin 5 Letrozole 5 Drug Therapy 5 Topotecan 3 Megestrol Acetate 3 Medroxyprogesterone Acetate 3 Bevacizumab 3 spartalizumab 2 olaparib 2 niraparib 2 Taxes 2 Methotrexate 2 Imiquimod 2 Hyperthermic Intraperitoneal Chemotherapy 2 Gonadotropin-Releasing Hormone 2 Gemcitabine 2 Doxorubicin 2 trametinib 1 sintilimab 1 saracatinib 1 ricin A-GnRH conjugate 1 pertuzumab 1 pegfilgrastim 1 netupitant, palosentron drug combination 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 mirabegron 1 masitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00418574 2011-11-24

MIMOSA

Menarini Group

Phase 2/3 Terminated

888 enrolled 17 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡